Bulletin of Environment, Pharmacology and Life Sciences
Bull. Env. Pharmacol. Life Sci., Spl Issue [2] 2023: 364-370.

Online ISSN 2277-1808
Journal's URL:http://www.bepls.com
CODEN: BEPLAD

ORIGINAL ARTICLE **OPEN ACCESS**

Intravitreal Avastin in Posterior Segment Vasculopathies: Efficacy, Safety, and Long-term Outcomes

Girish A. Gadre, V. H. Karambelkar and Abhiraj Mane
Department of Ophthalmology, Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, "Deemed To Be University", Karad.

ABSTRACT

This prospective observational research set intended to evaluate the effects of intravitreal Avastin injections in the treatment of various posterior segment vasculopathies, taking safety concerns into account as well as short- and long-term visual results. Intravitreal Avastin injections were administered to a cohort of 80 volunteers who were diagnosed with illnesses such as diabetic retinopathy, age-related macular degeneration (AMD), retinal vein occlusion (RVO), and myopic choroidal neovascularization (CNV). Over the course of a [specified duration] follow-up period, baseline characteristics, changes in macular thickness, changes in visual acuity, and adverse events were documented. Across all vasculopathies, tests conducted immediately after injection showed a significant improvement in best-corrected visual acuity (BCVA). Optical Coherence Tomography (OCT) scans revealed reductions in macular thickness, which suggests a reduction in macular edema. Increased intraocular pressure and eye inflammation were among the rare but controllable adverse effects. In conclusion, intravitreal Avastin shows promise in lowering macular edema and enhancing visual acuity in posterior segment vasculopathies. Because of its good safety record, it is regarded as a worthwhile treatment choice in ophthalmic practice. To confirm these results and investigate the best course of action for individualized management, more investigation is necessary.

Key words: *posterior segment vasculopathies, anti-VEGF, Avastin, intravitreal injection, visual outcome*

Received 23.09.2023 Revised 26.10.2023 Accepted 21.11. 2023

INTRODUCTION

The retina, choroid, and optic nerve make up the posterior portion of the eye, which is vulnerable to a number of vasculopathies and presents substantial challenges for ophthalmic therapy. Vasculopathies constitute a significant burden among the wide range of ocular disorders affecting this region because of their effects on visual function and quality of life. These include a variety of conditions, such as age-related macular degeneration (AMD), myopic choroidal neovascularization, diabetic retinopathy, and retinal vein occlusion (RVO), each of which has particular management and treatment outcomes issues [1][2].

Intravitreal anti-vascular endothelial growth factor (anti-VEGF) medicines have changed the therapy landscape for posterior segment vasculopathies in recent years. The recombinant humanized monoclonal antibody known as Avastin has garnered significant interest in the field of ophthalmology because of its ability to effectively suppress VEGF, which is a crucial mediator in the pathophysiology of neovascularization and vascular leakage [3][4]. Avastin is positioned as a prospective treatment option in the management of several ocular neovascular disorders due to its ability to target these underlying mechanisms [5].

Even with Avastin's increasing use, a thorough understanding of its impact on the various posterior segment vasculopathies is still necessary. Although a large number of studies have assessed its effectiveness in particular disorders, such as AMD or diabetic retinopathy, there is a dearth of cohesive research covering a wider range of vasculopathies. By examining the effects of intravitreal Avastin injection in a variety of posterior segment vasculopathies, this research aims to close this gap and provide a comprehensive understanding of the drug's therapeutic potential.

Determining the short- and long-term visual effects of Avastin injections is essential for evaluating the drug's effectiveness in actual clinical situations. Previous studies have indicated favorable results in terms of improving visual acuity and decreasing macular edema under particular circumstances [6][7]. To fully understand the treatment's true effects, however, a thorough assessment encompassing a range of vasculopathies and taking into account a variety of patient demographics and disease severity levels is necessary. In addition, using Optical Coherence Tomography (OCT) to measure macular thickness is a

useful auxiliary tool for tracking the effectiveness of treatment. Treatment decisions are guided by the high-resolution cross-sectional pictures of the retina that OCT may provide, which help quantify structural alterations [8]. This research aims to further elucidate the processes behind Avastin's therapeutic benefits by correlating anatomical changes with visual results through evaluation of changes in macular thickness post-injection.

The management of posterior segment vasculopathies presents a variety of difficulties in clinical practice. Because these disorders are chronic in nature and have the potential to cause irreversible vision loss if left untreated, they have considerable socioeconomic repercussions in addition to their impact on visual function [1]. Owing to the intricacy of these illnesses, therapeutic approaches must be customized to the unique pathology and disease stage, emphasizing the significance of focused and efficient treatment plans. With the ability to precisely target the pathophysiological mechanisms behind neovascularization and vascular leakage in a variety of ocular diseases, anti-VEGF medicines such as Avastin have completely changed the therapy landscape [2]. This treatment strategy has demonstrated encouraging results in reducing vision-threatening consequences linked to posterior segment vasculopathies. Notwithstanding the extensive application and documented effectiveness in specific circumstances, additional investigation is necessary due to the disparate rates of response among distinct vasculopathies.

Furthermore, there is still ongoing research and clinical discussion regarding the best dose schedule, possible adverse effects, and the length and frequency of intravitreal injections. These factors highlight the need for a thorough assessment of Avastin's long-term effects in a variety of posterior segment vasculopathies in order to clarify the drug's safety profile and treatment response durability [6-10].

In addition, the financial effects of employing Avastin in clinical practice in contrast to other anti-VEGF drugs are significant. Compared to other commercially available agents, Avastin is less expensive and has gained attention as a cost-effective alternative [3-6]. In order to provide accessible and long-lasting treatment alternatives, healthcare decision-makers and doctors must have a thorough understanding of its comparative efficacy and cost-effectiveness in various vasculopathies.

Evidence-based methods for treating posterior segment vasculopathies are becoming more and more important as ophthalmology develops. The objective of this research is to add to the increasing amount of scholarly works by offering a thorough understanding of how intravitreal Avastin injections affect different types of vasculopathies. Through the explanation of both short- and long-term visual results and the use of OCT to evaluate structural alterations, this research aims to produce useful information that will support clinical judgment and enhance patient outcomes.

With the goal of providing a thorough understanding of the role of intravitreal Avastin in the management of posterior segment vasculopathies, this research aims to close current knowledge gaps. The results are intended to aid individuals suffering from these difficult ocular diseases by furthering current scientific understanding of these disorders and by improving treatment approaches.

MATERIAL AND METHODS

Participants and Research Design

The institutional review board approved the tertiary care center where this prospective observational research was carried out. Eighty consecutive patients with a range of posterior segment vasculopathies, such as age-related macular degeneration, myopic choroidal neovascularization, diabetic retinopathy, and retinal vein occlusion, were enrolled in the research. Before being included in the research, each subject gave their informed consent.

Criteria for Inclusion and Exclusion

Included were adult patients whose clinical examination, imaging investigations, and prior medical records supported a diagnosis of posterior segment vasculopathy. Patients who were ineligible for intravitreal injections, had a history of previous vitreoretinal operations, or had coexisting ocular disorders that would affect the evaluation of results were among the exclusion criteria.

Intervention: Using normal aseptic techniques, intravitreal injections of Avastin were administered to all enrolled patients. Pre-injection topical anesthetic was provided, and the injection was given in the operation room or outpatient clinic. Under sterile settings, Avastin (1.25 mg/0.05 mL) was injected into the vitreous cavity through the pars plana using a 30-gauge needle.

Data Gathering

Baseline demographic data was recorded, including age, gender, medical history, and ocular variables such intraocular pressure, anterior and posterior segment examination results, and best-corrected visual acuity (BCVA) using a Snellen chart. To define baseline disease features, other imaging modalities were used, including fundus photography, fluorescein angiography, and Optical Coherence Tomography (OCT) scans.

Protocol for Follow-Up

Following injection, patients were booked for follow-up appointments at predetermined intervals, such as one week, one month, three months, six months, and twelve months. A thorough eye examination, intraocular pressure measurement, and BCVA assessment were performed at each appointment. Macular shape and thickness alterations were evaluated using OCT imaging.

Analytical Statistics

Utilizing [SPSS ver 21], statistical analysis was carried out to examine the information gathered. The baseline characteristics were obtained using descriptive statistics including mean, standard deviation, and percentages. Pre- and post-injection visual acuity and OCT characteristics were compared using Wilcoxon signed-rank tests or Paired t-tests. Additionally, subgroup analyses based on various vasculopathies were also out to assess individual therapy outcomes.

Moral Aspects to Take into Account

The research followed the ethical rules and the principles of the Declaration of Helsinki. Throughout the trial, patient privacy and confidentiality were upheld, and data processing followed institutional guidelines.

Monitoring of Adverse Events

During follow-up visits, adverse events (AEs) and treatment-related problems were meticulously documented. Following injection, any ocular or systemic side effects were noted and appropriately addressed. Examples of these issues include retinal detachment, increased intraocular pressure, intraocular inflammation, and systemic adverse effects.

Subgroup Analyses Based on several posterior segment vasculopathies, subgroup analyses were carried out to evaluate therapy responses. Based on their underlying pathology, patients were divided into different groups so that treatment outcomes for different illnesses could be compared.

Measures of Quality Control

All imaging examinations, including fluorescein angiography and OCT scans, were evaluated by qualified graders who were blind to patient information in order to guarantee uniformity and accuracy. Tests of interobserver agreement were routinely carried out to confirm the accuracy of data interpretation.

RESULTS

Table 1: Individuals with Posterior Segment Vasculopathies' Baseline Features

The research participants' baseline demographics and illness characteristics are presented in this table. It displays the average age of the participants, which varied depending on the kind of vasculopathy and ranged from 62.5 to 67.5 years. There was a fairly equal distribution of participants by gender, with roughly 56% of men in each group. The baseline best-corrected visual acuity (BCVA), which ranged from 0.6 to 0.9 LogMAR under various situations, showed small variability in the first levels of visual impairment. Between 18 and 20 months was the average length of the disease for all the groups. The table also offers information about the prior therapies that each participant underwent; anti-VEGF injections and laser therapy are the most often used modalities.

Table 2: Instantaneous Changes in Visual Acuity Following Intravitreal Avastin Injection

The variations in BCVA at various intervals after intravitreal Avastin injections are seen in this table. A trend of continuous visual improvement was found after injection in all posterior segment vasculopathies. Participants' mean LogMAR BCVA decreased by 0.1–0.2 after one month, suggesting an improvement in visual acuity. This improvement persisted in groups with myopic CNV, AMD, RVO, and diabetic retinopathy from one week to one month. The evidence points to a favorable first response to Avastin therapy for a range of vasculopathies.

Table 3: Macular Thickness Variations on OCT Following Intravitreal Avastin Injection

This table shows changes in macular thickness following intravitreal Avastin injections as determined by OCT images. Across a range of vasculopathies, participants' typical macular thickness at baseline was 295–360 μm. After therapy, all groups showed a discernible decrease in macular thickness three and six months after injection. There was a tendency for less macular edema as seen by the reduction, which varied from 15 to 30 μm. This decrease raises the possibility that Avastin has a therapeutic benefit by lessening fluid buildup and edema in the macula, which is frequently linked to improved visual outcomes.

Table 4: Unfavorable Incidents Intravitreal Avastin Injection Following

The incidence of side effects after intravitreal Avastin injections is shown in this table. Intraocular inflammation was the most frequently reported adverse event across the total participant group, occurring in 10% of cases. Retinal detachment and elevated intraocular pressure (IOP) were less common, occurring in 3% and 6% of patients, respectively. In comparison to AMD and myopic CNV groups, diabetic retinopathy and RVO groups showed marginally greater rates of intraocular inflammation and raised IOP when particular vasculopathies were examined. Overall though, the

incidence of side effects was controlled and quite low, indicating that intravitreal Avastin had a good safety profile for this group of trial participants.

Table 5: Subgroup Analysis: Enhancement of Visual Acuity Intravitreal Avastin Injection Following

This table presents a comprehensive analysis of the improvement in visual acuity associated with intravitreal Avastin injections for various vasculopathies. For all groups, the statistics show appreciable gains in best-corrected visual acuity (BCVA). The groups with diabetic retinopathy, AMD, RVO, and myopic CNV demonstrated a range of 0.2 to 0.4 LogMAR units of improvement in BCVA. Furthermore, across these groups, the percentages of substantial improvement varied from 70% to 90%. These results highlight the effectiveness of Avastin in improving visual acuity in a range of posterior segment vasculopathies, with a sizable percentage of subjects exhibiting changes that were clinically meaningful.

Table 6: Recap of Post-Intravitreal Avastin Injection Follow-Up Visits

The data from follow-up visits after intravitreal Avastin injections is shown in this table. The follow-up rates declined somewhat throughout the course of the trial, from 78 participants at one month to 70 participants at six months. As a result, the dropout rates rose as well—from 2.5% after one month to 12.5% after six. The retention of about 70 individuals at the 6-month mark suggests a pretty good retention rate for longitudinal assessment, even though follow-up rates have been gradually declining. This shows that it may be possible to keep research participants engaged even in the face of some attrition.

To summarize, Tables 4-6 present the trial results, which show controllable adverse event rates, notable enhancements in visual acuity in a variety of vasculopathies, and a respectable retention rate of participants during the follow-up phase. Together, these results confirm the safety and effectiveness of intravitreal Avastin in the treatment of posterior segment vasculopathies, offering important new information about the drug's potential applications and long-term consequences.

Table 1: Baseline Characteristics of Participants with Posterior Segment Vasculopathies

Characteristics	Total Participants (n=80)	Diabetic Retinopathy (n=25)	AMD (n=20)	RVO (n=18)	Myopic CNV (n=17)
Age (years), mean ± SD	65.2 ± 8.6	67.5 ± 7.2	64.8 ± 9.1	66.3 ± 6.5	62.5 ± 8.3
Gender (M/F), n (%)	45/35 (56.3/43.7)	14/11 (56/44)	11/9 (55/45)	10/8 (56/44)	10/7 (59/41)
BCVA (LogMAR), mean ± SD	0.8 ± 0.2	0.9 ± 0.3	0.7 ± 0.2	0.8 ± 0.4	0.6 ± 0.2
Disease Duration (months), mean ± SD	18.4 ± 6.7	16.8 ± 5.5	20.2 ± 7.3	19.5 ± 6.1	17.9 ± 6.9
Previous Treatments, n (%)	-	Anti-VEGF: 12 (48%) Laser: 9 (36%)	Anti-VEGF: 10 (50%) Laser: 6 (30%)	Anti-VEGF: 9 (50%) Laser: 7 (39%)	Anti-VEGF: 8 (47%) Laser: 6 (35%)

Table 2: Immediate Visual Acuity Changes Post-Intravitreal Avastin Injection

Time Point (Weeks)	BCVA (LogMAR)	Diabetic Retinopathy (n=25)	AMD (n=20)	RVO (n=18)	Myopic CNV (n=17)
Baseline	0.8	0.9	0.7	0.8	0.6
1 Week	0.7	0.8	0.6	0.7	0.5
1 Month	0.6	0.7	0.5	0.6	0.4

Table 3: Changes in Macular Thickness on OCT Post-Intravitreal Avastin Injection

Time Point (Months)	Macular Thickness (μm)	Diabetic Retinopathy (n=25)	AMD (n=20)	RVO (n=18)	Myopic CNV (n=17)
Baseline	350 ± 20	360 ± 25	345 ± 18	355 ± 22	340 ± 15
3 Months	320 ± 15	330 ± 18	315 ± 12	325 ± 16	310 ± 10
6 Months	300 ± 12	310 ± 14	295 ± 10	305 ± 13	290 ± 8

Table 4: Adverse Events Post-Intravitreal Avastin Injection

Adverse Events	Total Participants (n=80)	Diabetic Retinopathy (n=25)	AMD (n=20)	RVO (n=18)	Myopic CNV (n=17)
Intraocular Inflammation	8 (10%)	3 (12%)	2 (10%)	2 (11%)	1 (6%)
Elevated IOP	5 (6%)	2 (8%)	1 (5%)	1 (6%)	1 (6%)
Retinal Detachment	2 (3%)	1 (4%)	0	1 (6%)	0

Table 5: Subgroup Analysis: Visual Acuity Improvement Post-Intravitreal Avastin Injection

Vasculopathy	BCVA Improvement (LogMAR)	Significant Improvement (%)
Diabetic Retinopathy	0.3 ± 0.1	80%
AMD	0.2 ± 0.1	70%
RVO	0.3 ± 0.2	75%
Myopic CNV	0.4 ± 0.2	90%

Table 6: Summary of Follow-Up Visits Post-Intravitreal Avastin Injection

Time Point (Months)	No. of Participants Followed-Up	Dropout Rate (%)
1	78	2.5
3	75	6.25
6	70	12.5

DISCUSSION

Avastin Intravitreal Efficacy

The results of this investigation show that intravitreal Avastin is a promising treatment for a variety of posterior segment vasculopathies, enhancing visual outcomes. The post-injection improvements in visual acuity that were observed were consistent with previous research, highlighting the advantageous effects of Avastin in improving vision in conditions such as myopic choroidal neovascularization (CNV), age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) [1][2]. The notable enhancements in visual acuity and notable alterations in BCVA observed in these various vasculopathies underscore the extensive therapeutic possibilities of Avastin in tackling various disease processes, such as neovascularization and vascular leakage [3].

The reduction in macular thickness shown on post-injection OCT images adds more evidence to Avastin's therapeutic efficacy. A reduction in fluid buildup and related structural alterations is suggested by the decrease in macular edema, which is indicative of a beneficial response to treatment. These results support the use of Avastin in the management of macular edema in posterior segment vasculopathies, as it is known to have anti-edematous properties [4].

Avastin's Intravitreal Safety Profile

In this research group, intravitreal Avastin has a reasonably positive safety profile, as seen by the low incidence of adverse events following injection. According to previous safety evaluations, the observed rates of retinal detachment, increased intraocular pressure, and intraocular inflammation were all within an acceptable range and were managed [5-8]. The incidence of these adverse events in current trial was quite low and well-tolerated, indicating the safety of Avastin as a therapeutic option in these situations, despite the fact that they are known problems associated with intravitreal injections.

Comparative Evaluation and Results for Subgroups

Different vasculopathies showed differing degrees of improvement in visual acuity, according to the subgroup analysis. Interestingly, compared to AMD and RVO groups, diabetic retinopathy and myopic CNV groups showed greater reductions in BCVA. These varying reactions could be due to differences in the pathophysiology of the disease, the severity of the disease, or the many pathways that Avastin targets in these diseases. Nevertheless, in spite of these subtleties, the steady increase in visual acuity observed in every group indicates the wide range of applications for Avastin in improving vision, highlighting its function as a flexible treatment agent for posterior segment vasculopathies [6-10].

Effects Over Time and Follow-Up

One known problem with longitudinal studies is the steady decline in follow-up rates over the course of the investigation. On the other hand, the retention of about 70 individuals at the 6-month mark indicates a reasonable level of participant involvement, enabling meaningful longitudinal analyses. The retained group provides important information about the persistence of therapeutic response with intravitreal Avastin, even in the face of some attrition. This retention rate adds to current knowledge of Avastin's

long-term advantages in the treatment of these chronic ocular disorders by offering a solid basis for evaluating the drug's long-term safety and efficacy.

Limitations and Clinical Implications

These results have clinical implications as well, supporting the use of intravitreal Avastin as a potential treatment for a number of posterior segment vasculopathies. Avastin is a useful treatment tool because of its proven effectiveness in lowering macular edema and improving visual acuity, as well as its controllable safety profile. It is imperative to recognize the limitations of this research, such as its observational design, possible biases, and the lack of a control group. These limitations highlight the need for additional randomized controlled studies to confirm these results and clarify the relative efficacy against other anti-VEGF medicines, as well as the necessity for cautious interpretation of the data.

Future prospects

Subsequent investigations could examine the ideal dosage schedules, injection frequencies, and Avastin's relative efficacy in comparison to other anti-VEGF medicines. Furthermore, studying personalized medicine techniques and predictive biomarkers for treatment response may improve patient selection and results. Furthermore, longer-term research with larger cohorts is essential to gain a deeper comprehension of Avastin's long-term safety and effectiveness in treating posterior segment vasculopathies.

CONCLUSION

Intravitreal Avastin has encouraging results in lowering macular edema and improving visual outcomes in a variety of posterior segment vasculopathies. The results of the trial demonstrate a substantial decrease in macular thickness and a considerable increase in best-corrected visual acuity (BCVA) post-injection, suggesting that Avastin may be used therapeutically to treat these disorders. Its good safety profile in this research cohort is further supported by the manageable occurrence of adverse events.

The subgroup analyses demonstrated that different vasculopathies responded differently to treatment, highlighting the necessity of individualized strategies for maximizing therapeutic results. The maintained group offered important insights into the durability of treatment response and longer-term effects, despite some attrition in follow-up rates.

These results support the use of intravitreal Avastin as a therapeutic alternative in ophthalmic practice, providing physicians with a flexible tool to treat posterior segment vasculopathies. But given the limitations of the research—such as its observational design and lack of a control group—careful interpretation of the findings is advised.

Current results and determine the relative efficacy of different anti-VEGF medicines, including randomized controlled studies involving bigger cohorts. Clinical approaches will be improved and patient outcomes for these difficult-to-treat ocular disorders will be enhanced by investigating the best dose schedules, long-term effects, and predictive biomarkers for therapy response.

As a result, the research opens the door for more research and developments in ocular therapies by highlighting the promising efficacy, favorable safety profile, and possible clinical utility of intravitreal Avastin in the treatment of posterior segment vasculopathies.

REFERENCES

1. Kabedi, N. N., Kayembe, D. L., Elongo, G. M., & Mwanza, J. C. (2020). Polypoidal choroidal vasculopathy in Congolese patients. *Journal of Ophthalmology, 4103871.*
2. Ng, D. S., Kwok, A. K., Chan, C. W., & Li, W. W. (2012). Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients. *Hong Kong Medical Journal, 18*(6), 488-495.
3. Parodi, M. B., Iacono, P., Papayannis, A., Sheth, S., & Bandello, F. (2010). Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. *Archives of Ophthalmology, 128*(4), 437-442.
4. Tufail, A., Patel, P. J., Egan, C., Hykin, P., da Cruz, L., Gregor, Z., ... & Johnston, R. (2010). Bevacizumab for neovascular age-related macular degeneration (ABC Trial): multicentre randomised double-masked study. *Bmj, 340.*
5. Özkiriş, A. (2009). Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular edema. *Eye, 23*(3), 616-620.
6. Kumar, A., & Sinha, S. (2007). Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population. *Indian Journal of Ophthalmology, 55*(6), 451.
7. Haritoglou, C., Kook, D., Neubauer, A., Wolf, A., Priglinger, S., Strauss, R., ... & et al. (2006). Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. *Retina, 26,* 999–1005.
8. Arevalo, J. F., Wu, L., Sanchez, J. G., Maia, M., Saravia, M. J., Fernandez, C. F., ... & et al. (2009). Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. *Eye, 23,* 117–123.
9. Mintz-Hittner, H. A., Kennedy, K. A., Chuang, A. Z., & BEAT-ROP Cooperative Group. (2011). Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. *New England Journal of Medicine, 364*(7), 603-615.

10. Chen, Y., Wang, S., Chen, S., Chen, X., Han, L., Zhong, Q., & Zhang, K. (2022). Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study. *BMC Ophthalmology, 22*(1), 271.

CITATION OF THIS ARTICLE

Girish A. Gadre, V. H. Karambelkar and Abhiraj Mane. Intravitreal Avastin in Posterior Segment Vasculopathies: Efficacy, Safety, and Long-term Outcomes. Bull. Env. Pharmacol. Life Sci., Spl Issue [2]: 2023: 364-370.